πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 373 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 7872096

Methods for cyclizing synthetic polymers

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jan 18 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 13 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7872000

Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as Axl inhibitors

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jan 18 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 13 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7868013

Cycloalkyl substituted pyrimidinediamine compounds and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jan 11 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 06 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7863286

Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jan 04 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7858633

Cycloalkyl substituted pyrimidinediamine compounds and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Dec 28 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 23 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7851480

Spiro 2,4-pyrimidinediamine compounds and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Dec 14 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 09 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7834024

Compositions and methods for inhibition of the JAK pathway

Rigel Pharmaceuticals, Inc. Β· Granted Tue Nov 16 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7825116

N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines

Rigel Pharmaceuticals, Inc. Β· Granted Tue Nov 02 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7820819

2,4-pyrimidinediamine compounds and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Oct 26 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 21 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7812029

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

Rigel Pharmaceuticals, Inc. Β· Granted Tue Oct 12 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 07 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7803939

2,4-pyrimidinediamine compounds and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Sep 28 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 23 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7776847

Benzisothiazoles useful for treating or preventing HCV infection

Rigel Pharmaceuticals, Inc. Β· Granted Tue Aug 17 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 12 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7754714

Cycloalkyl substituted pyrimidinediamine compounds and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jul 13 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 08 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7723018

Methods of assaying for cell cycle modulators using components of the ubiquitin ligation c

Rigel Pharmaceuticals, Inc. Β· Granted Tue May 25 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 20 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7714137

Pyridyl substituted heterocycles useful for treating or preventing HCV infection

Rigel Pharmaceuticals, Inc. Β· Granted Tue May 11 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 06 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7713987

Pyrimidine-2,4-diamines and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue May 11 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 06 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7709482

Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors

Rigel Pharmaceuticals, Inc. Β· Granted Tue May 04 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 29 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7659280

2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases

Rigel Pharmaceuticals, Inc. Β· Granted Tue Feb 09 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7655797

Intermediates for making 2,4-pyrimidinediamine compounds

Rigel Pharmaceuticals, Inc. Β· Granted Tue Feb 02 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7601713

Kinase inhibitors and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Oct 13 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 08 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7589200

5-Fluoro-4N-phenyl-4-pyrimidineamine compounds

Rigel Pharmaceuticals, Inc. Β· Granted Tue Sep 15 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7585883

Substituted pyridines and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Sep 08 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7582648

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

Rigel Pharmaceuticals, Inc. Β· Granted Tue Sep 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7576053

Methods and compositions for treating degenerative bone disorders

Rigel Pharmaceuticals, Inc. Β· Granted Tue Aug 18 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 13 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted